Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?

Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes.

Detalles Bibliográficos
Autor principal: Donath, Marc Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685630/
https://www.ncbi.nlm.nih.gov/pubmed/33248018
http://dx.doi.org/10.1016/j.cmet.2020.11.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685630/
https://www.ncbi.nlm.nih.gov/pubmed/33248018
http://dx.doi.org/10.1016/j.cmet.2020.11.015

Ejemplares similares